

May 25-27, 2021 | Exclusive Virtual Summit

7:30am - 5:30pm EST

[www.sting-tlr-targeting-therapies.com](http://www.sting-tlr-targeting-therapies.com)

Book Before Friday,  
February 26 & Save  
Up To \$800!



# STING & TLR-Targeting Therapies

Summit DIGITAL

Plus Innate Immune Checkpoints & Activation Pre-Focus Day

10.25 | 7.25

## **TL-532, the First Rationally Designed TLR3 Agonist Creates Long-Lasting Tumor Specific Immunity *In Vivo***

- TL-532, a double stranded RNA of 70 base pairs has been designed to obtain optimal dual action of immune cell stimulation and cancer cell apoptosis
- In vitro TLR3 specificity and TLR3 specific cell death by apoptosis has been demonstrated in multiple cancer cell lines. Comparing its activity on normal versus cancer cells, TL-532 demonstrates an optimal profile and potential best-in-class TLR3 agonist
- In vivo activity of TL532 has been demonstrated in the syngeneic MBT2 mice model with substantial tumor growth delay and survival benefits. Long lasting tumor specific immunity has been demonstrated by rechallenging complete responders to TL-532 treatment one year later: More than 70% showed long term autovaccination by totally preventing tumor development after two consecutive rechallenges with tumor cells



**Bettina Werle**  
Chief Scientific  
Officer  
Tollys